The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.
The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.
复制标题
DOI：
--
复制
发表时间：
2006
期刊：
影响因子：
10.1
通讯作者：
J. Nojima;Y. Iwatani;E. Suehisa;H. Kuratsune;Y. Kanakura
中科院分区：
文献类型：
--
作者：
J. Nojima;Y. Iwatani;E. Suehisa;H. Kuratsune;Y. Kanakura
为了阐明酶联免疫吸附试验（ELISA）检测抗磷脂抗体（aPL）的临床意义，我们检测了抗心磷脂抗体（aCL）、抗β 2-糖蛋白I抗体和抗β 2-糖蛋白I抗体的患病率。（抗β 2-GPI），抗凝血酶原抗体（抗PT），检测175例系统性红斑狼疮（SLE）患者（包括67例血栓性并发症）的抗磷脂酰丝氨酸/凝血酶原抗体（抗PS/PT）。本研究表明，抗β 2-GPI-ELISA和抗PS/PT-ELISA阳性结果可作为SLE患者血栓性并发症的标志物，而aCL和抗PT作为这些并发症的标志物的可靠性较低。此外，抗PS/PT-ELISA的结果与SLE患者动脉和静脉血栓形成的发生最相关。
In an effort to clarify the clinical significance of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA), we examined the prevalence of anti-cardiolipin antibodies (aCL), anti-beta2-glycoprotein I antibodies (anti-beta2-GPI), antiprothrombin antibodies (anti-PT), and anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) in 175 patients with systemic lupus erythematosus (SLE) comprising 67 patients with thrombotic complications. The present study showed that positive results of anti-beta2-GPI-ELISA and anti-PS/PT-ELISA could serve as markers of thrombotic complications in patients with SLE, whereas aCL and anti-PT are less reliable as markers of these complications. Furthermore, results of the anti-PS/PT-ELISA correlate best with the occurrence of both arterial and venous thrombosis in patients with SLE.